Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rabeprazole on Vadadustat PK in Healthy Adults
NCT03789032Phase 1Completed
- Sponsor
- Akebia Therapeutics
- Start
- Oct 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vadadustat in anemia of chronic kidney disease (CKD-A), sponsored by Akebia Therapeutics. Primary endpoints: Area under plasma concentration-time curve from 0 to last quantifiable concentration at 48 hours, Area under plasma concentration-time curve from 0 to infinity at 48 hours and 1 more. Started Oct 2018; status: completed.
02
Drugs
vadadustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT03789032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03789032.